CL2017000372A1 - Composiciones novedosas, usos y métodos para hacerlas. - Google Patents

Composiciones novedosas, usos y métodos para hacerlas.

Info

Publication number
CL2017000372A1
CL2017000372A1 CL2017000372A CL2017000372A CL2017000372A1 CL 2017000372 A1 CL2017000372 A1 CL 2017000372A1 CL 2017000372 A CL2017000372 A CL 2017000372A CL 2017000372 A CL2017000372 A CL 2017000372A CL 2017000372 A1 CL2017000372 A1 CL 2017000372A1
Authority
CL
Chile
Prior art keywords
methods
make
novel compositions
compounds
compositions
Prior art date
Application number
CL2017000372A
Other languages
English (en)
Inventor
Mustapah Haddach
Original Assignee
Pimera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54393079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000372(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pimera Inc filed Critical Pimera Inc
Publication of CL2017000372A1 publication Critical patent/CL2017000372A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

<p>GENERALMENTE, LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS DE QUINOLONA NOVEDOSOS Y COMPOSICIÓN FARMACÉUTICA DE LOS MISMOS QUE PUEDEN INHIBIR LA PROLIFERACIÓN CELULAR Y/O INDUCIR LA APOPTOSIS CELULAR. LA PRESENTE INVENCIÓN TAMBIÉN PROPORCIONA MÉTODOS PARA PREPARAR TALES COMPUESTOS Y COMPOSICIONES, Y MÉTODOS PARA FABRICAR Y USAR EL MISMO.</p>
CL2017000372A 2014-05-09 2017-02-13 Composiciones novedosas, usos y métodos para hacerlas. CL2017000372A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461991282P 2014-05-09 2014-05-09
US201462050202P 2014-09-15 2014-09-15
US201462054054P 2014-09-23 2014-09-23
US201562128208P 2015-03-04 2015-03-04

Publications (1)

Publication Number Publication Date
CL2017000372A1 true CL2017000372A1 (es) 2017-09-08

Family

ID=54393079

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2016002798A CL2016002798A1 (es) 2014-05-09 2016-11-04 Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón.
CL2017000372A CL2017000372A1 (es) 2014-05-09 2017-02-13 Composiciones novedosas, usos y métodos para hacerlas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2016002798A CL2016002798A1 (es) 2014-05-09 2016-11-04 Compuestos derivados de triciclos nitrogenados que contienen una naftiridina condensada con un bencimidazol y su uso como inhibidores de la proliferación celular para el tratamiento del cáncer de pulmón, colorrectal, hígado, páncreas, ganglio linfático, colon, próstata, cerebro, cabeza y cuello, piel, riñón sangre o corazón.

Country Status (32)

Country Link
US (1) US9512123B2 (es)
EP (2) EP3140305B1 (es)
JP (2) JP6188179B2 (es)
KR (3) KR102044648B1 (es)
CN (2) CN106995443B (es)
AU (3) AU2015255738C1 (es)
BR (1) BR112016026150B1 (es)
CA (2) CA2948173C (es)
CL (2) CL2016002798A1 (es)
CY (1) CY1120935T1 (es)
DK (1) DK3140305T3 (es)
EA (1) EA034235B1 (es)
EC (3) ECSP16088687A (es)
ES (1) ES2679628T3 (es)
HR (1) HRP20181105T1 (es)
HU (1) HUE039733T2 (es)
IL (2) IL248638B (es)
LT (1) LT3140305T (es)
MX (1) MX2016014555A (es)
NI (1) NI201600168A (es)
NZ (1) NZ725917A (es)
PE (2) PE20170131A1 (es)
PH (2) PH12016502213B1 (es)
PL (1) PL3140305T3 (es)
PT (1) PT3140305T (es)
RS (1) RS57493B1 (es)
SG (2) SG11201609171XA (es)
SI (1) SI3140305T1 (es)
TR (1) TR201809990T4 (es)
UA (1) UA117182C2 (es)
WO (1) WO2015172123A1 (es)
ZA (1) ZA201607573B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
EP3601286A4 (en) * 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE SHAPES OF A POL1 INHIBITOR
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN112300173B (zh) * 2019-07-30 2021-10-01 上海凌达生物医药有限公司 一类含氮多环类化合物、制备方法和用途
JP2023509260A (ja) 2019-08-14 2023-03-08 インサイト・コーポレイション Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
CN110606850A (zh) * 2019-09-11 2019-12-24 中山大学 一种3-苯并[4,5]咪唑[1,2-a]吡嗪-1-胺类化合物及其制备方法和应用
KR20220099970A (ko) 2019-10-11 2022-07-14 인사이트 코포레이션 Cdk2 억제제로서의 이환식 아민
CN114685487B (zh) * 2020-12-27 2024-04-19 上海凌达生物医药有限公司 一类嘧啶并杂环类化合物、制备方法和用途
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN113416197B (zh) * 2021-08-25 2021-12-28 北京鑫开元医药科技有限公司 甲酰胺类衍生物、制备方法、药物组合物及应用
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114276354B (zh) * 2022-01-07 2023-06-02 中山大学 1-氨基苯并[4,5]咪唑并[1,2-a]吡嗪-3-甲酰胺类化合物及其制备和应用
CN114539265B (zh) * 2022-03-02 2023-07-21 中山大学 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7709746A (nl) * 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
DE2929414A1 (de) * 1979-07-20 1981-02-05 Hoechst Ag Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung
DE3502689A1 (de) * 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt Elektrophotographisches aufzeichnungsmaterial
ATE157665T1 (de) * 1992-06-22 1997-09-15 Boehringer Ingelheim Kg 9-amino-pyridazino 4',5' : 3,4>pyrrolo- 2,1- a>isochinoline und deren verwendung für die herstellung von pharmazeutischen zubereitungen
DE19509043A1 (de) * 1995-03-03 1996-09-05 Bayer Ag Cyanierung von Doppelbindungssystemen
US6960585B2 (en) 2000-10-03 2005-11-01 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US7354916B2 (en) 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
JP2006522827A (ja) 2003-04-07 2006-10-05 サイリーン ファーマシューティカルズ インコーポレーティッド 置換キノベンゾオキサジン類似体
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
JP2008513485A (ja) 2004-09-17 2008-05-01 サイリーン ファーマシューティカルズ インコーポレーティッド キノロンアナログ
ITMI20042476A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Derivati indolici ad attivita' antitumorale
US7402579B2 (en) 2005-04-15 2008-07-22 Cylene Pharmaceuticals, Inc. Quinobenzoxazine analogs and compositions
DK1928887T3 (en) 2005-08-05 2015-03-23 Senhwa Biosciences Inc Methods for preparing quinolonanaloger
EP2270014A1 (en) * 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
EP2023720A4 (en) * 2006-05-17 2009-06-10 Cylene Pharmaceuticals Inc TETRACYCLIC IMIDAZOLE ANALOGS
DE102006051796A1 (de) 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo[e]azulenderivate
WO2008156879A1 (en) 2007-06-20 2008-12-24 Universal Display Corporation Blue phosphorescent imidazophenanthridine materials
RU2549895C2 (ru) 2007-10-05 2015-05-10 Сенхва Байосайенсиз,Инк. Аналоги хинолона и относящиеся к ним способы
CA2731368C (en) 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
CN103333167B (zh) 2008-11-03 2016-08-24 株式会社Lg化学 新的含氮杂环化合物及使用该化合物的有机电子器件
US8124770B2 (en) 2009-04-01 2012-02-28 Beatriz Zayas Fluorescent cellular markers
CN101781312B (zh) * 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 一种吲哚衍生物的合成方法
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
WO2012123938A1 (en) * 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
KR101561730B1 (ko) * 2012-02-06 2015-10-22 주식회사 엘지화학 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자

Also Published As

Publication number Publication date
KR20160144509A (ko) 2016-12-16
US9512123B2 (en) 2016-12-06
CA2948173A1 (en) 2015-11-12
PE20170678A1 (es) 2017-06-03
PH12016502213A1 (en) 2017-01-16
JP2017101038A (ja) 2017-06-08
IL264454A (en) 2019-02-28
CL2016002798A1 (es) 2017-03-10
ES2679628T3 (es) 2018-08-29
IL248638B (en) 2019-02-28
KR20180118806A (ko) 2018-10-31
EP3219716A1 (en) 2017-09-20
KR101890505B1 (ko) 2018-09-28
RS57493B1 (sr) 2018-10-31
ECSP17031525A (es) 2017-06-30
AU2015255738A1 (en) 2016-11-24
US20160326176A1 (en) 2016-11-10
AU2017202145A1 (en) 2017-04-20
AU2015255738C1 (en) 2017-09-28
CN106995443B (zh) 2022-01-11
SI3140305T1 (sl) 2018-09-28
ECSP18049420A (es) 2018-07-31
CA2948173C (en) 2018-06-19
EP3140305A1 (en) 2017-03-15
NI201600168A (es) 2017-01-26
CN106459068A (zh) 2017-02-22
KR20170042821A (ko) 2017-04-19
AU2017203955A1 (en) 2017-07-06
CN106995443A (zh) 2017-08-01
PH12016502213B1 (en) 2017-01-16
SG10201703658SA (en) 2017-06-29
AU2017202145B2 (en) 2019-02-21
EP3140305B1 (en) 2018-04-18
CN106459068B (zh) 2019-01-22
BR112016026150B1 (pt) 2019-11-05
NZ725917A (en) 2017-07-28
HRP20181105T1 (hr) 2018-09-21
JP2017514889A (ja) 2017-06-08
CY1120935T1 (el) 2019-12-11
PH12017500660A1 (en) 2019-03-04
DK3140305T3 (en) 2018-07-30
AU2015255738B2 (en) 2017-04-27
WO2015172123A1 (en) 2015-11-12
ZA201607573B (en) 2018-08-30
PL3140305T3 (pl) 2018-10-31
EA034235B1 (ru) 2020-01-20
SG11201609171XA (en) 2016-12-29
KR102044648B1 (ko) 2019-11-13
EP3140305A4 (en) 2017-03-15
PT3140305T (pt) 2018-07-24
UA117182C2 (uk) 2018-06-25
EA201692269A1 (ru) 2017-04-28
ECSP16088687A (es) 2017-01-31
MX2016014555A (es) 2017-05-30
HUE039733T2 (hu) 2019-01-28
LT3140305T (lt) 2018-09-10
JP6188179B2 (ja) 2017-08-30
CA2974960A1 (en) 2015-11-12
TR201809990T4 (en) 2018-08-27
PE20170131A1 (es) 2017-03-19

Similar Documents

Publication Publication Date Title
CL2017000372A1 (es) Composiciones novedosas, usos y métodos para hacerlas.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
PH12018500718A1 (en) Compounds useful as modulators of trpm8
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2017000576A1 (es) Inhibidores de mk2 y sus usos
EA201890052A1 (ru) Регуляторы nrf2
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
CR20150316A (es) Compuestos y sus métodos de empleo
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CL2017001046A1 (es) Inhibidoes del bromodominio
CO2017011152A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx / ca.
ECSP18018793A (es) Compuestos útiles para inhibir ror-gamma-t
UY37017A (es) Inhibidores aza-bencimidazol de pad4
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017007377A (es) Compuestos organicos.
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
DOP2016000211A (es) Pirazinas moduladoras de gpr6
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
CU20180044A7 (es) Derivados novedosos de diamino piridina
MX2017007380A (es) Compuestos organicos.
CU20170134A7 (es) 2-tiopirimidinonas